Shulman DeMeo Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $392K | Sell |
16,281
-327
| -2% | -$8.55K | 0.07% | 93 |
|
|
2026
Q1 | $466K | Buy |
16,608
+94
| +0.6% | +$2.5K | 0.1% | 73 |
|
|
2025
Q4 | $411K | Sell |
16,514
-122
| -0.7% | -$3.08K | 0.09% | 74 |
|
|
2025
Q3 | $424K | Buy |
16,636
+79
| +0.5% | +$1.95K | 0.1% | 78 |
|
|
2025
Q2 | $401K | Sell |
16,557
-443
| -3% | -$10.3K | 0.1% | 74 |
|
|
2025
Q1 | $431K | Buy |
17,000
+126
| +0.7% | +$3.3K | 0.12% | 67 |
|
|
2024
Q4 | $448K | Sell |
16,874
-5,130
| -23% | -$139K | 0.12% | 67 |
|
|
2024
Q3 | $637K | Sell |
22,004
-3,209
| -13% | -$93.6K | 0.16% | 52 |
|
|
2024
Q2 | $705K | Sell |
25,213
-5,031
| -17% | -$139K | 0.18% | 45 |
|
|
2024
Q1 | $839K | Buy |
30,244
+172
| +0.6% | +$4.77K | 0.22% | 37 |
|
|
2023
Q4 | $866K | Sell |
30,072
-1,940
| -6% | -$58.6K | 0.25% | 35 |
|
|
2023
Q3 | $1.06M | Sell |
32,012
-129
| -0.4% | -$4.56K | 0.35% | 27 |
|
|
2023
Q2 | $1.18M | Sell |
32,141
-237
| -0.7% | -$9.22K | 0.35% | 27 |
|
|
2023
Q1 | $1.32M | Sell |
32,378
-6
| -0% | -$259 | 0.41% | 19 |
|
|
2022
Q4 | $1.66M | Buy |
32,384
+28
| +0.1% | +$1.34K | 0.55% | 17 |
|
|
2022
Q3 | $1.42M | Sell |
32,356
-326
| -1% | -$15.8K | 0.5% | 18 |
|
|
2022
Q2 | $1.71M | Buy |
32,682
+494
| +2% | +$25.2K | 0.57% | 14 |
|
|
2022
Q1 | $1.67M | Sell |
32,188
-1,048
| -3% | -$54.4K | 0.46% | 20 |
|
|
2021
Q4 | $1.96M | Buy |
33,236
+1,152
| +4% | +$57.1K | 0.51% | 17 |
|
|
2021
Q3 | $1.38M | Buy |
+32,084
| New | +$1.42M | 1.2% | 15 |
|
|
2021
Q2 | – | Sell |
-32,207
| Closed | -$1.17M | – | 122 |
|
|
2021
Q1 | $1.17M | Buy |
32,207
+2,002
| +7% | +$71.1K | 0.32% | 37 |
|
|
2020
Q4 | $1.11M | Buy |
30,205
+1,005
| +3% | +$36.9K | 0.32% | 37 |
|
|
2020
Q3 | $1.02M | Buy |
29,200
+1,060
| +4% | +$37.2K | 0.34% | 35 |
|
|
2020
Q2 | $873K | Buy |
28,140
+353
| +1% | +$12K | 0.34% | 34 |
|
|
2020
Q1 | $860K | Buy |
27,787
+1,847
| +7% | +$62.9K | 0.4% | 31 |
|
|
2019
Q4 | $964K | Sell |
25,940
-2,205
| -8% | -$78.5K | 0.33% | 36 |
|
|
2019
Q3 | $959K | Buy |
28,145
+2,064
| +8% | +$75.1K | 0.32% | 38 |
|
|
2019
Q2 | $1.07M | Buy |
26,081
+5,271
| +25% | +$209K | 0.4% | 29 |
|
|
2019
Q1 | $839K | Buy |
+20,810
| New | +$833K | 0.32% | 34 |
|
Other funds holding PFE
Shulman DeMeo Asset Management's PFE Position: Q2 2026 in Review
Shulman DeMeo Asset Management reduced its Pfizer (PFE) stake by 2% in Q2 2026, selling an estimated $8.55K and leaving 16,281 shares worth $392K. The position accounts for 0.07% of the portfolio, ranked #93.
Shulman DeMeo Asset Management first reported a position in PFE in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.96M in Q4 2021. 2,833 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Shulman DeMeo Asset Management held 16,281 shares of Pfizer worth $392K as of Q2 2026.
- Shulman DeMeo Asset Management sold 327 Pfizer shares in Q2 2026, an estimated $8.55K.
- Pfizer made up 0.07% of Shulman DeMeo Asset Management's portfolio in Q2 2026, its #93 holding.
- Shulman DeMeo Asset Management first reported a position in Pfizer in Q1 2019 and has held it in 29 quarters since.
- Shulman DeMeo Asset Management's Pfizer position peaked at $1.96M in Q4 2021.
- 2,833 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Shulman DeMeo Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.